Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Oxogestone phenpropionate

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Oxogestone phenpropionate
Clinical data
Other namesOxogesterone phenpropionate; Xinogestone; Oxageston; 20β-Hydroxy-19-norprogesterone phenylpropionate; 20β-Dihydro-19-norprogesterone 20β-(3-phenylpropionate); 20β-Hydroxy-19-norpregn-4-en-3-one 20β-(3-phenylpropionate); (20R)-3-Oxo-19-norpregn-4-en-20-yl 3-phenylpropanoate
Routes of
administration		intramuscular injection
Drug classProgestogen;Progestogen ester
Identifiers
  • [(1R)-1-[(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl] 3-phenylpropanoate
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC29H38O3
Molar mass434.620 g·mol−1
3D model (JSmol)
  • CC(C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)OC(=O)CCC5=CC=CC=C5
  • InChI=1S/C29H38O3/c1-19(32-28(31)15-8-20-6-4-3-5-7-20)26-13-14-27-25-11-9-21-18-22(30)10-12-23(21)24(25)16-17-29(26,27)2/h3-7,18-19,23-27H,8-17H2,1-2H3/t19-,23+,24-,25-,26-,27+,29-/m1/s1
  • Key:LHPBUFXEIOLURH-GQZONRFDSA-N

Oxogestone phenpropionate (OPP;USANTooltip United States Adopted Name) (former developmental code name or tentative brand nameOxageston), also known asxinogestone, as well as20β-hydroxy-19-norprogesterone 20β-(3-phenylpropionate), is aprogestin related to the19-norprogesterone derivatives which was developed as aninjectablehormonal contraceptive, specifically aprogestogen-only injectable contraceptive, in the 1960s and early 1970s but was never marketed.[1][2][3][4][5][6][7] It was studied at a dose of 50 to 75 mg once a month byintramuscular injection but was associated with a high failure rate with this regimen and was not further developed.[5] OPP is the 20β-(3-phenylpropionate)ester ofoxogestone, which, similarly, was never marketed.[1]

Parenteral potencies and durations of progestogens[a][b]
CompoundFormDose for specific uses (mg)[c]DOA[d]
TFD[e]POICD[f]CICD[g]
Algestone acetophenideOil soln.––75–15014–32 d
Gestonorone caproateOil soln.25–50––8–13 d
Hydroxyprogest. acetate[h]Aq. susp.350––9–16 d
Hydroxyprogest. caproateOil soln.250–500[i]–250–5005–21 d
Medroxyprog. acetateAq. susp.50–1001502514–50+ d
Megestrol acetateAq. susp.––25>14 d
Norethisterone enanthateOil soln.100–2002005011–52 d
ProgesteroneOil soln.200[i]––2–6 d
Aq. soln.?––1–2 d
Aq. susp.50–200––7–14 d
Notes and sources:
  1. ^Sources:[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]
  2. ^All given byintramuscular orsubcutaneous injection.
  3. ^Progesterone production during theluteal phase is ~25 (15–50) mg/day. TheOIDTooltip ovulation-inhibiting dose of OHPC is 250 to 500 mg/month.
  4. ^Duration of action in days.
  5. ^Usually given for 14 days.
  6. ^Usually dosed every two to three months.
  7. ^Usually dosed once monthly.
  8. ^Never marketed or approved by this route.
  9. ^abIn divided doses (2 × 125 or 250 mg forOHPC, 10 × 20 mg forP4).

See also

[edit]

References

[edit]
  1. ^abJ. Elks (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 919–.ISBN 978-1-4757-2085-3.
  2. ^George W.A Milne (8 May 2018).Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1577–.ISBN 978-1-351-78989-9.
  3. ^van der Vies, J. (1970). "Model studies in vitro with long-acting hormonal preparations".Acta Endocrinologica.64 (4):656–669.doi:10.1530/acta.0.0640656.ISSN 0804-4643.PMID 5468664.
  4. ^Heeres, S. G. (1967). Preliminary results with a long-acting progestational preparation. In: Wood, C. and Walters, W.A., eds. Fifth World Congress of Gynaecology and Obstetrics, Sydney, September 1967. New York Appleton-Century-Crofts, 1967. p. 348http://www.popline.org/node/475027
  5. ^abToppozada M (June 1977). "The clinical use of monthly injectable contraceptive preparations".Obstet Gynecol Surv.32 (6):335–47.doi:10.1097/00006254-197706000-00001.PMID 865726.
  6. ^Petrow V (1970). "The contraceptive progestagens".Chem. Rev.70 (6):713–26.doi:10.1021/cr60268a004.PMID 4098492.
  7. ^Mokhtar K. Toppozada (1983). "Monthly Injectable Contraceptives". In Alfredo Goldsmith; Mokhtar Toppozada (eds.).Long-Acting Contraception. pp. 93–103.OCLC 35018604.
  8. ^Knörr K, Beller FK, Lauritzen C (17 April 2013).Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–.ISBN 978-3-662-00942-0.
  9. ^Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C (8 March 2013).Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–.ISBN 978-3-642-95583-9.
  10. ^Labhart A (6 December 2012).Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 554–.ISBN 978-3-642-96158-8.
  11. ^Horský J, Presl J (1981)."Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl K (eds.).Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332.doi:10.1007/978-94-009-8195-9_11.ISBN 978-94-009-8195-9.
  12. ^Ufer J (1969).The Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics. de Gruyter. p. 49.ISBN 9783110006148.17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle.
  13. ^Pschyrembel W (1968).Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598, 601.ISBN 978-3-11-150424-7.
  14. ^Ferin J (September 1972)."Effects, Duration of Action and Metabolism in Man". In Tausk M (ed.).Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 13–24.ISBN 978-0080168128.OCLC 278011135.
  15. ^Henzl MR, Edwards JA (10 November 1999). "Pharmacology of Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". In Sitruk-Ware R, Mishell DR (eds.).Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 101–132.ISBN 978-0-8247-8291-7.
  16. ^Brotherton J (1976).Sex Hormone Pharmacology. Academic Press. p. 114.ISBN 978-0-12-137250-7.
  17. ^Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives".Contraception.49 (4):361–385.doi:10.1016/0010-7824(94)90033-7.PMID 8013220.
  18. ^Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives".Contraception.49 (4):293–301.doi:10.1016/0010-7824(94)90029-9.PMID 8013216.
  19. ^Goebelsmann U (1986)."Pharmacokinetics of Contraceptive Steroids in Humans". In Gregoire AT, Blye RP (eds.).Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111.doi:10.1007/978-1-4613-2241-2_4.ISBN 978-1-4613-2241-2.
  20. ^Becker H, Düsterberg B, Klosterhalfen H (1980). "[Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)]" [Bioavailability of Cyproterone Acetate after Oral and Intramuscular Application in Men].Urologia Internationalis.35 (6):381–385.doi:10.1159/000280353.PMID 6452729.
  21. ^Moltz L, Haase F, Schwartz U, Hammerstein J (May 1983). "[Treatment of virilized women with intramuscular administration of cyproterone acetate]" [Efficacy of Intra muscularly Applied Cyproterone Acetate in Hyperandrogenism].Geburtshilfe und Frauenheilkunde.43 (5):281–287.doi:10.1055/s-2008-1036893.PMID 6223851.
  22. ^Wright JC, Burgess DJ (29 January 2012).Long Acting Injections and Implants. Springer Science & Business Media. pp. 114–.ISBN 978-1-4614-0554-2.
  23. ^Chu YH, Li Q, Zhao ZF (April 1986)."Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive".The Chinese Journal of Clinical Pharmacology.The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days.
  24. ^Runnebaum BC, Rabe T, Kiesel L (6 December 2012).Female Contraception: Update and Trends. Springer Science & Business Media. pp. 429–.ISBN 978-3-642-73790-9.
  25. ^Artini PG, Genazzani AR, Petraglia F (11 December 2001).Advances in Gynecological Endocrinology. CRC Press. pp. 105–.ISBN 978-1-84214-071-0.
  26. ^King TL, Brucker MC, Kriebs JM, Fahey JO (21 October 2013).Varney's Midwifery. Jones & Bartlett Publishers. pp. 495–.ISBN 978-1-284-02542-2.
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists


Stub icon

Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it.

Stub icon

This article about asteroid is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Oxogestone_phenpropionate&oldid=1134398440"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp